Year-End report January – December 2025

SyntheticMR reported Q4 sales of SEK 18.0m (up 42% y/y) and a reduced operating loss of SEK -5.3m (Q4 2024: -7.5m), but full-year 2025 results show revenue of SEK 57.0m (+2%) alongside a much larger operating loss of SEK -49.3m and net loss SEK -54.9m after impairments; cash at year-end stood at SEK 7.4m (vs SEK 51.0m). The company completed the Combinostics acquisition (FY revenue SEK 12.9m, ARR SEK 11.7m), secured multiple regulatory approvals (Europe, India, Japan, South Korea) for cMRI/SyMRI products, and completed a near-fully subscribed rights issue to shore up the balance sheet — signaling commercial progress but significant near-term profitability and liquidity challenges.

Analysis

Market structure: SyntheticMR’s approvals in Europe, India and APAC OEM traction make OEM MRI vendors (GE Healthcare, Siemens Healthineers, Philips) and hospital MRI service providers the primary beneficiaries as software shifts value from scanners to recurring platform fees. Research-dependent vendors and academic sales channels are losers given softer U.S. research grant flows; expect pricing pressure on one-off SyMRI research packages but rising pricing power for subscription-based analytics (ARR up 38% y/y to SEK 11.7m). Supply/demand: secular demand for ARIA/Alzheimer’s monitoring increases MRI scan volumes (high single-digit CAGR industry implication), expanding addressable market but favoring vendors with OEM/recurring models.

Risk assessment: Tail risks include a materially higher-than-expected cash burn leading to another equity raise (cash fell to SEK 7.4m from 51m), regulatory reversals in major markets, or failed OEM integrations that impair commercial scalability. Immediate (days) risk is post-rights volatility; short-term (3–6 months) risk is execution on U.S. commercial reboot; long-term (12–24 months) risk is margin compression if OEM deals are white-label. Hidden dependencies: revenue visibility tied to OEM contract terms, reclassification of contracts to pay-per-use reduces near-term ARR recognition and elongates sales cycles. Key catalysts: 1) next quarterly ARR growth rate, 2) announced U.S. OEM partnership or major hospital contract, 3) quarter-over-quarter cash burn falling below SEK 5m.

Trade implications: Speculative, size-constrained long exposure to SyntheticMR is warranted only after rights-issue stabilization; hedge with long positions in GE (GE) or Philips (PHG) to capture OEM upside. Use limited-risk options (12-month call spreads) rather than naked calls on illiquid small-cap stock; rotate capital away from research-dependent small-cap MedTech into recurring-revenue software and large OEMs over 3–12 months. Entry window: wait 5–20 trading days after rights allotment to assess secondary market liquidity and confirm cash runway; exit or trim if cash < SEK 3m or another dilution announced.

Contrarian angle: The market is underpricing the structural upside from ARIA-driven recurring demand — if SyntheticMR converts OEM interest into integrated, revenue-sharing deals ARR could accelerate >30% y/y and justify >2x current enterprise multiple. Conversely, consensus may underestimate dilution risk; historical parallels include software-acquisition rollups that initially trade down then re-rate after ARR inflection (e.g., early SaaS consolidation cases). Unintended consequence: deep OEM integration could commoditize software features, capping unit economics but expanding scale; prepare for either high-volume/low-margin or low-volume/high-margin outcomes.

Key Decisions for Investors

• Establish a tactical 1–2% long position in SyntheticMR AB shares (name) only after (a) the post-rights-issue price holds above the issue price for 5 trading days and (b) next quarter cash burn is confirmed ≤ SEK 5m; target 12–24 month upside 100–150%, stop-loss at 35% below entry.
• Rotate 2–4% portfolio weight from research-dependent small-cap MedTech into large OEM exposures: split equally into GE (GE) and Philips (PHG), hold 6–12 months to capture OEM software integration tailwinds; add on any pullback >10% from entry.
• If options access is available, buy defined-risk 12-month call spreads on GE or PHG (buy 20% OTM, sell 40% OTM) sized to 0.5–1% portfolio risk to capture MRI OEM upside; avoid buying illiquid SyntheticMR options unless spreads narrow.
• Monitor three hard triggers over the next 90 days — (1) ARR q/q growth >5%, (2) US commercial win or OEM contract announced, (3) quarterly cash burn ≤ SEK 5m — and increase SyntheticMR exposure to 3–5% only if two of three are met; if cash < SEK 3m or another equity raise is announced, exit within one week.